The First Clinical Medical School, Lanzhou University, Lanzhou, China.
Can J Cardiol. 2013 Feb;29(2):196-203. doi: 10.1016/j.cjca.2012.03.019. Epub 2012 Jun 7.
The effects of omega-3 fatty acids (PUFA) on the prevention of atrial fibrillation (AF) appear to contrast between several randomized controlled trials (RCTs). Therefore, we performed a meta-analysis to assess the efficacy and safety of PUFA for the primary and secondary prevention of AF.
PubMed, EMBASE, Web of Science, Cochrane Library and the Chinese Biomedical Literature Database were searched for randomized controlled trials (published up to January 2012) that compared PUFA with control. All statistical analyses were performed with RevMan (version 5.1; The Cochrane Collaboration, Oxford, United Kingdom).
For primary prevention after open heart surgery: 6 studies with 928 patients were designed to evaluate the effects of PUFA on the incidence of postoperative AF. The use of PUFA significantly reduced the incidence of postoperative AF (odds ratio [OR] 0.66; 95% confidence interval [CI], 0.49 to 0.88; P = 0.004); there was no difference in complications or adverse events (OR, 1.24; 95% CI, 0.58-2.62; P = 0.58). For secondary prevention, we analyzed 5 studies involving 1256 patients designed to evaluate the effects of PUFA therapy on AF. The use of PUFA did not significantly reduce the recurrence of AF (OR, 0.74; 95% CI, 0.39-1.42; P = 0.37); no difference was observed in complications or adverse events (OR, 1.10; 95% CI, 0.78-1.57; P = 0.58).
The meta-analysis shows that PUFA therapy is significantly associated with a decreased odds of incidence of AF after open heart surgery, but there is no significant difference in recurrence of AF between PUFA and control groups. PUFA is well-tolerated, with no difference in complications or adverse events between PUFA and control groups.
ω-3 脂肪酸（PUFA）对心房颤动（AF）预防的作用在几项随机对照试验（RCT）中似乎存在差异。因此，我们进行了一项荟萃分析，以评估 PUFA 对 AF 的一级和二级预防的疗效和安全性。
检索了 PubMed、EMBASE、Web of Science、Cochrane Library 和中国生物医学文献数据库，以获取比较 PUFA 与对照组的随机对照试验（截至 2012 年 1 月发表）。所有统计分析均使用 RevMan（版本 5.1；Cochrane 协作组，英国牛津）进行。
对于心脏直视手术后的一级预防：6 项研究共 928 例患者旨在评估 PUFA 对术后 AF 发生率的影响。使用 PUFA 可显著降低术后 AF 的发生率（比值比[OR]0.66；95%置信区间[CI]，0.49 至 0.88；P=0.004）；并发症或不良事件无差异（OR，1.24；95%CI，0.58 至 2.62；P=0.58）。对于二级预防，我们分析了 5 项涉及 1256 例患者的研究，旨在评估 PUFA 治疗对 AF 的影响。使用 PUFA 不能显著降低 AF 的复发率（OR，0.74；95%CI，0.39 至 1.42；P=0.37）；并发症或不良事件无差异（OR，1.10；95%CI，0.78 至 1.57；P=0.58）。
荟萃分析表明，PUFA 治疗与心脏直视手术后 AF 发生率降低显著相关，但 PUFA 组与对照组之间 AF 的复发无显著差异。PUFA 具有良好的耐受性，PUFA 组与对照组之间的并发症或不良事件无差异。
